SCHEMBL68191

SCHEMBL68191

Oc1c(Cl)cc(Cl)c(O)c1Cl

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 11/20 0.77
TSHR P16473 9/20 0.77
HPGD P15428 9/20 0.77
MAPK1 P28482 3/20 0.77
CASP1 P29466 2/20 0.65
CYP3A4 P08684 7/20 0.56
ALDH1A1 P00352 5/20 0.56
RECQL P46063 3/20 0.56
TTR P02766 3/20 0.56
ALOX15 P16050 4/20 0.55
ALOX12 P18054 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MEN1 O00255 4/20 0.55
LMNA P02545 4/20 0.55
MAPT P10636 4/20 0.55
KMT2A Q03164 4/20 0.55
THRB P10828 3/20 0.55
HIF1A Q16665 3/20 0.55
HSP90AA1 P07900 3/20 0.55
HTR1A P08908 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL54380 0.87 HSD17B10 (1.00) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL29364629 0.87 HSD17B10 (1.00) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL11879785 0.84 HSD17B10 (0.57) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL30631745 0.80 HSD17B10 (0.77) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL11832897 0.80 HSD17B10 (0.77) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL9623619 0.80 HSD17B10 (0.60) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL11144843 0.80 HSD17B10 (0.59) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL11713810 0.80 HSD17B10 (0.59) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL10771021 0.80 HSD17B10 (0.59) HSD17B10TSHRHPGDMAPK1CASP1
SCHEMBL827930 0.79 HSD17B10 (1.00) HSD17B10TSHRHPGDMAPK1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179849-B2 Antimicrobial compositions containing colloids of oligodynamic metals C. R. BARD, INC. (US) 2007-02-20 US claimed
US-20050042266-A1 Cyanoacrylate compositions containing anti-microbial agent CLOSURE MEDICAL CORPORATION (US) 2005-02-24 US claimed
EP-1508601-A1 Cyanoacrylate compositions containing anti-microbial agent Closure Medical Corporation (US) 2005-02-23 EP claimed
EP-2948256-B1 ANTISEPTIC APPLICATOR CAREFUSION 2200 INC (US) 2022-12-14 EP disclosed
US-20200299671-A1 IMMOBILIZED MULTI-ENZYMATIC HALOGENATION SYSTEM UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2020-09-24 US disclosed
EP-2173428-B1 FOLEY CATHETER HAVING STERILE BARRIER BARD INC C R (US) 2018-10-10 EP disclosed
CN-103338732-B Feminine care absorbent article for use in warm climates 金伯利-克拉克环球有限公司 2016-08-10 CN disclosed
EP-2948256-A1 ANTISEPTIC APPLICATOR CareFusion 2200 Inc. (US) 2015-12-02 EP disclosed
CN-104955585-A ANTISEPTIC APPLICATOR CAREFUSION 2200 INC 2015-09-30 CN disclosed
US-9119946-B2 Antiseptic applicator CAREFUSION 2200, INC. (US) 2015-09-01 US disclosed
US-9084838-B2 Feminine care absorbent article for use in warm climates KIMBERLY-CLARK WORLDWIDE, INC. (US) 2015-07-21 US disclosed
US-20010016589-A1 Mixture of chlorhexidine, quaternary ammonium salt and chlorinated phenol TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2001-08-23 US disclosed
EP-0664014-B1 NLO SIDE CHAIN POLYMERS HAVING LOW OPTICAL LOSS AKZO NOBEL NV (NL) 1998-08-19 EP disclosed
EP-0824096-A2 Process for the preparation of halogenated (meth)acrylic esters and poly (meth) arcylates obtained with said (meth)acrylic esters Akzo Nobel N.V. (NL) 1998-02-18 EP disclosed
EP-0664014-A1 NLO SIDE CHAIN POLYMERS HAVING LOW OPTICAL LOSS Akzo Nobel N.V. (NL) 1995-07-26 EP disclosed
WO-1994008269-A1 NLO SIDE CHAIN POLYMERS HAVING LOW OPTICAL LOSS AKZO NOBEL N.V. (NL) 1994-04-14 WO disclosed
EP-0319990-B1 Process for preparing composite membranes DU PONT (US) 1993-10-20 EP disclosed
EP-0319990-A2 Process for preparing composite membranes E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-06-14 EP disclosed
US-4783346-A INTERFACES, POLYAMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-11-08 US disclosed
US-4155946-A CATALYST CONSISTS OF A NICKEL COMPOUND, A TRIALKYL ALUMINUM COMPOUND; PHOSPHOROUS COMPOUND AND A HALOGENATED PHENOL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050042266-A1 Cyanoacrylate compositions containing anti-microbial agent CLSPN, PCNA, CDC73 HSD17B10 3029/4885TSHR 4429/4885HPGD 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.